EA037151B1 - Способ лечения с использованием пегилированного интерферона - Google Patents
Способ лечения с использованием пегилированного интерферона Download PDFInfo
- Publication number
- EA037151B1 EA037151B1 EA201790991A EA201790991A EA037151B1 EA 037151 B1 EA037151 B1 EA 037151B1 EA 201790991 A EA201790991 A EA 201790991A EA 201790991 A EA201790991 A EA 201790991A EA 037151 B1 EA037151 B1 EA 037151B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- interferon
- treatment period
- weeks
- subject
- administered
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 67
- 238000000034 method Methods 0.000 title claims description 34
- 102000014150 Interferons Human genes 0.000 title claims description 19
- 108010050904 Interferons Proteins 0.000 title claims description 19
- 229940079322 interferon Drugs 0.000 title claims description 11
- 102000002227 Interferon Type I Human genes 0.000 claims abstract description 36
- 108010014726 Interferon Type I Proteins 0.000 claims abstract description 36
- 208000014767 Myeloproliferative disease Diseases 0.000 claims abstract description 15
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 9
- 102100040018 Interferon alpha-2 Human genes 0.000 claims description 9
- 108010079944 Interferon-alpha2b Proteins 0.000 claims description 9
- 230000009467 reduction Effects 0.000 claims description 9
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 8
- 230000002489 hematologic effect Effects 0.000 claims description 8
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 7
- 210000000265 leukocyte Anatomy 0.000 claims description 7
- 208000032027 Essential Thrombocythemia Diseases 0.000 claims description 6
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims description 6
- 238000004820 blood count Methods 0.000 claims description 6
- 206010000830 Acute leukaemia Diseases 0.000 claims description 5
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 5
- 208000017733 acquired polycythemia vera Diseases 0.000 claims description 5
- 238000005534 hematocrit Methods 0.000 claims description 5
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 5
- 208000037244 polycythemia vera Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 229920001427 mPEG Polymers 0.000 claims description 4
- 206010028537 myelofibrosis Diseases 0.000 claims description 4
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 claims description 3
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 claims description 3
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 claims description 3
- 101001126417 Homo sapiens Platelet-derived growth factor receptor alpha Proteins 0.000 claims description 3
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 claims description 3
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 claims description 3
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims description 3
- 208000019420 lymphoid neoplasm Diseases 0.000 claims description 3
- 201000006462 myelodysplastic/myeloproliferative neoplasm Diseases 0.000 claims description 3
- 238000010606 normalization Methods 0.000 claims description 3
- 208000035473 Communicable disease Diseases 0.000 abstract description 6
- 201000011510 cancer Diseases 0.000 abstract description 5
- 208000015181 infectious disease Diseases 0.000 abstract description 5
- 230000004044 response Effects 0.000 description 16
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 10
- 102100040019 Interferon alpha-1/13 Human genes 0.000 description 9
- 229940047124 interferons Drugs 0.000 description 8
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 description 7
- 208000025321 B-lymphoblastic leukemia/lymphoma Diseases 0.000 description 7
- 108010047761 Interferon-alpha Proteins 0.000 description 7
- 102000006992 Interferon-alpha Human genes 0.000 description 7
- 108010092851 peginterferon alfa-2b Proteins 0.000 description 7
- 229940106366 pegintron Drugs 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000012423 maintenance Methods 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 4
- 230000012953 feeding on blood of other organism Effects 0.000 description 4
- 230000006842 hematologic response Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 208000009527 Refractory anemia Diseases 0.000 description 3
- 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- 201000010374 Down Syndrome Diseases 0.000 description 2
- 206010058314 Dysplasia Diseases 0.000 description 2
- 208000036566 Erythroleukaemia Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010033661 Pancytopenia Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 208000021841 acute erythroid leukemia Diseases 0.000 description 2
- 238000010009 beating Methods 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 208000024389 cytopenia Diseases 0.000 description 2
- 230000002435 cytoreductive effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000000925 erythroid effect Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000037451 immune surveillance Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 229940002988 pegasys Drugs 0.000 description 2
- 108010092853 peginterferon alfa-2a Proteins 0.000 description 2
- 230000004983 pleiotropic effect Effects 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- 208000016557 Acute basophilic leukemia Diseases 0.000 description 1
- 206010000871 Acute monocytic leukaemia Diseases 0.000 description 1
- 208000026661 Acute myeloid leukemia with 11q23 abnormalities Diseases 0.000 description 1
- 208000037532 Acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2) Diseases 0.000 description 1
- 208000010581 Acute myeloid leukemia with minimal differentiation Diseases 0.000 description 1
- 206010000890 Acute myelomonocytic leukaemia Diseases 0.000 description 1
- 208000016585 Acute panmyelosis with myelofibrosis Diseases 0.000 description 1
- 208000025363 B-lymphoblastic leukemia/lymphoma with TCF3-PBX1 Diseases 0.000 description 1
- 208000025359 B-lymphoblastic leukemia/lymphoma with hypodiploidy Diseases 0.000 description 1
- 208000037172 B-lymphoblastic leukemia/lymphoma with recurrent genetic abnormality Diseases 0.000 description 1
- 208000037398 BCR-ABL1 negative atypical chronic myeloid leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000033775 Basophilic Acute Leukemia Diseases 0.000 description 1
- 206010008583 Chloroma Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000037379 Myeloid Chronic Atypical BCR-ABL Negative Leukemia Diseases 0.000 description 1
- 208000033835 Myelomonocytic Acute Leukemia Diseases 0.000 description 1
- 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 description 1
- 208000037538 Myelomonocytic Juvenile Leukemia Diseases 0.000 description 1
- 208000033755 Neutrophilic Chronic Leukemia Diseases 0.000 description 1
- 108091008121 PML-RARA Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 108700019889 TEL-AML1 fusion Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000013593 acute megakaryoblastic leukemia Diseases 0.000 description 1
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 description 1
- 208000026784 acute myeloblastic leukemia with maturation Diseases 0.000 description 1
- 208000010816 acute myeloblastic leukemia without maturation Diseases 0.000 description 1
- 208000019159 acute myeloid leukemia with t(6;9)(p23;q34) Diseases 0.000 description 1
- 208000011912 acute myelomonocytic leukemia M4 Diseases 0.000 description 1
- 208000036676 acute undifferentiated leukemia Diseases 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 201000004892 atypical chronic myeloid leukemia Diseases 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000019574 childhood myelodysplastic syndrome Diseases 0.000 description 1
- 208000021668 chronic eosinophilic leukemia Diseases 0.000 description 1
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 description 1
- 201000010903 chronic neutrophilic leukemia Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 108010045648 interferon omega 1 Proteins 0.000 description 1
- 108700027921 interferon tau Proteins 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 201000005992 juvenile myelomonocytic leukemia Diseases 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 208000008585 mastocytosis Diseases 0.000 description 1
- 208000022769 mixed phenotype acute leukemia Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 201000005987 myeloid sarcoma Diseases 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- VBJGJHBYWREJQD-UHFFFAOYSA-M sodium;dihydrogen phosphate;dihydrate Chemical compound O.O.[Na+].OP(O)([O-])=O VBJGJHBYWREJQD-UHFFFAOYSA-M 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000003813 thin hair Effects 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000009424 thromboembolic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14192114 | 2014-11-06 | ||
| PCT/US2015/059410 WO2016073825A1 (en) | 2014-11-06 | 2015-11-06 | Dosage regimen for pegylated interferon |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201790991A1 EA201790991A1 (ru) | 2017-11-30 |
| EA037151B1 true EA037151B1 (ru) | 2021-02-11 |
Family
ID=51945707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201790991A EA037151B1 (ru) | 2014-11-06 | 2015-11-06 | Способ лечения с использованием пегилированного интерферона |
Country Status (32)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7189399B2 (ja) * | 2017-01-18 | 2022-12-14 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 骨髄増殖性障害を患う患者の処置のための方法及び医薬組成物 |
| US11414698B2 (en) * | 2018-03-22 | 2022-08-16 | Chang Gung Medical Foundation Chang Gung Memorial Hospital At Chiayi | Method of quantifying mutant allele burden of target gene |
| WO2021216801A1 (en) * | 2020-04-22 | 2021-10-28 | Southlake Pharmaceuticals, Inc. | Pegylated interferon tau and compositions and methods thereof |
| AU2022221496A1 (en) * | 2021-08-29 | 2023-03-16 | Pharmaessentia Corporation | Method of Using Pegylated Interferon-alpha |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5382657A (en) * | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
| US5738846A (en) * | 1994-11-10 | 1998-04-14 | Enzon, Inc. | Interferon polymer conjugates and process for preparing the same |
| US20090035273A1 (en) * | 2006-08-18 | 2009-02-05 | Pepgen Corporation | Combination treatment method with interferon-tau |
| US20120310140A1 (en) * | 2010-12-01 | 2012-12-06 | Spinal Modulation, Inc. | Directed delivery of agents to neural anatomy |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5951974A (en) | 1993-11-10 | 1999-09-14 | Enzon, Inc. | Interferon polymer conjugates |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| TW517067B (en) * | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
| US6824768B2 (en) * | 1998-12-18 | 2004-11-30 | Schering Corporation | Ribavirin-pegylated interferon alfa induction HCV combination therapy |
| RU2002105485A (ru) * | 1999-08-13 | 2004-01-27 | Ф.Хоффманн-Ля Рош Аг (Ch) | Применение микофенолята мофетила в сочетании с ПЭГ-интерфероном-α (ПЭГ-IFN-α) |
| HUP0302674A2 (hu) | 1999-08-27 | 2003-11-28 | Maxigen Aps. | Új, béta-interferon-szerű molekulák |
| HRP20020387A2 (en) | 1999-11-12 | 2005-10-31 | Maxygen Holdings Ltd. | Interferon gamma conjugates |
| US7125843B2 (en) | 2001-10-19 | 2006-10-24 | Neose Technologies, Inc. | Glycoconjugates including more than one peptide |
| OA13063A (en) | 2001-11-20 | 2006-11-10 | Pharmacia Corp | Chemically-modified human growth hormone conjugates. |
| US20030171285A1 (en) | 2001-11-20 | 2003-09-11 | Finn Rory F. | Chemically-modified human growth hormone conjugates |
| EE05509B1 (et) | 2002-01-18 | 2012-02-15 | Biogen@Idec@Ma@Inc | Aktiveeritud polalkleenglkoolpolmeer ja seda sisaldavad kompositsioonid |
| US7345150B2 (en) | 2002-03-26 | 2008-03-18 | Medical University Of Toledo | Albumin-based colloid composition having at least one protected thiol region, methods of making, and methods of use |
| AU2003270454B2 (en) | 2002-09-09 | 2010-05-20 | Nektar Therapeutics | Water-soluble polymer alkanals |
| US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| MXPA05006945A (es) | 2002-12-26 | 2005-12-14 | Mountain View Pharmaceuticals | Conjugados polimericos de citoquinas, quimiocinas, factores de crecimiento, hormonas polipeptidicas y sus antagonistas con actividad conservada de union al receptor. |
| JP5048332B2 (ja) | 2003-05-23 | 2012-10-17 | ネクター セラピューティクス | 特定の原子配置を有するポリマー誘導体 |
| CA2547140A1 (en) | 2003-11-24 | 2005-06-09 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
| KR20070042567A (ko) | 2004-08-31 | 2007-04-23 | 파마시아 앤드 업존 캄파니 엘엘씨 | 글리세롤 분지쇄 폴리에틸렌 글리콜 인간 성장 호르몬공액체, 이의 제조 방법 및 이의 사용 방법 |
| US7365127B2 (en) | 2005-02-04 | 2008-04-29 | Enzon Pharmaceuticals, Inc. | Process for the preparation of polymer conjugates |
| EP1869079A2 (en) | 2005-03-11 | 2007-12-26 | Siegfried Ltd. | Di-polymer protein conjugates and processes for their preparation |
| WO2006094530A1 (en) | 2005-03-11 | 2006-09-14 | Siegfried Ltd. | Di-polymer protein conjugates and processes for their preparation |
| CN101002944B (zh) | 2006-01-17 | 2012-07-25 | 中国科学院过程工程研究所 | 支链聚乙二醇-干扰素结合物及其制备方法 |
| EP1834963A1 (en) | 2006-03-13 | 2007-09-19 | Siegfried Ltd. | Di-polymer protein conjugates and processes for their preparation |
| CN101104078B (zh) | 2006-07-11 | 2011-11-02 | 北京美倍他药物研究有限公司 | 多肽及蛋白药物的聚乙二醇偶合物 |
| CN101108895B (zh) | 2006-07-19 | 2011-10-26 | 北京键凯科技有限公司 | 聚乙二醇乙醛衍生物及其与药物的结合物 |
| CN1966547B (zh) | 2006-11-06 | 2011-11-09 | 中国药科大学 | 双链结构的聚乙二醇衍生物的制备及其与药物分子的结合 |
| CN1970572A (zh) | 2006-12-21 | 2007-05-30 | 北京三元基因工程有限公司 | 干扰素α突变体及其聚乙二醇衍生物 |
| CL2008002399A1 (es) | 2007-08-16 | 2009-01-02 | Pharmaessentia Corp | Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c. |
| PT2196475E (pt) | 2007-09-04 | 2012-09-07 | Biosteed Gene Expression Tech Co Ltd | Interferão alfa-2a modificado por polietilenoglicol, seu processo de síntese e aplicação |
| ATE548382T1 (de) * | 2007-09-04 | 2012-03-15 | Biosteed Gene Expression Tech Co Ltd | Polyethylenglykolmodifiziertes interferon alpha 2b und herstellungsverfahren und anwendungen davon |
| CN101491682A (zh) | 2008-04-30 | 2009-07-29 | 北京凯正生物工程发展有限责任公司 | 聚乙二醇化重组人干扰素ω偶合物及其制备工艺 |
| US8273343B2 (en) | 2008-07-31 | 2012-09-25 | Pharmaessentia Corp. | Protein-polymer conjugates |
| CN101671390B (zh) | 2008-09-10 | 2012-10-03 | 海南四环心脑血管药物研究院有限公司 | 人干扰素α衍生物及其聚乙二醇化修饰物的制备和用途 |
| CN101514229B (zh) | 2009-04-03 | 2012-05-09 | 海南四环心脑血管药物研究院有限公司 | 人干扰素α衍生物及其聚乙二醇化修饰物 |
| UA109646C2 (uk) | 2009-12-10 | 2015-09-25 | Терапевтичне застосування кон'югатів білка з полімером |
-
2015
- 2015-11-06 NZ NZ730924A patent/NZ730924A/en unknown
- 2015-11-06 ES ES15857703T patent/ES2966888T3/es active Active
- 2015-11-06 WO PCT/US2015/059410 patent/WO2016073825A1/en not_active Ceased
- 2015-11-06 HK HK18102667.8A patent/HK1243627A1/zh unknown
- 2015-11-06 AU AU2015342908A patent/AU2015342908B2/en active Active
- 2015-11-06 EP EP15857703.1A patent/EP3215193B1/en active Active
- 2015-11-06 EA EA201790991A patent/EA037151B1/ru unknown
- 2015-11-06 PT PT158577031T patent/PT3215193T/pt unknown
- 2015-11-06 DK DK15857703.1T patent/DK3215193T3/da active
- 2015-11-06 LT LTEPPCT/US2015/059410T patent/LT3215193T/lt unknown
- 2015-11-06 SI SI201531980T patent/SI3215193T1/sl unknown
- 2015-11-06 US US15/518,423 patent/US11559567B2/en active Active
- 2015-11-06 UA UAA201705540A patent/UA122867C2/uk unknown
- 2015-11-06 PL PL15857703.1T patent/PL3215193T3/pl unknown
- 2015-11-06 CA CA2964390A patent/CA2964390A1/en active Pending
- 2015-11-06 KR KR1020237018405A patent/KR102724837B1/ko active Active
- 2015-11-06 RS RS20231262A patent/RS65015B1/sr unknown
- 2015-11-06 KR KR1020177015233A patent/KR102540109B1/ko active Active
- 2015-11-06 SM SM20240028T patent/SMT202400028T1/it unknown
- 2015-11-06 SG SG11201702798PA patent/SG11201702798PA/en unknown
- 2015-11-06 HR HRP20231732TT patent/HRP20231732T1/hr unknown
- 2015-11-06 TW TW104136693A patent/TWI737583B/zh active
- 2015-11-06 CN CN201580058159.1A patent/CN107530403A/zh active Pending
- 2015-11-06 EP EP23199969.9A patent/EP4282485A3/en active Pending
- 2015-11-06 FI FIEP15857703.1T patent/FI3215193T3/fi active
- 2015-11-06 MY MYPI2017701335A patent/MY191506A/en unknown
- 2015-11-06 HU HUE15857703A patent/HUE064909T2/hu unknown
- 2015-11-06 MX MX2017005244A patent/MX389844B/es unknown
- 2015-11-06 JP JP2017519649A patent/JP6820841B2/ja active Active
- 2015-11-06 PH PH1/2017/500617A patent/PH12017500617B1/en unknown
- 2015-11-06 BR BR112017009193-3A patent/BR112017009193A2/pt not_active Application Discontinuation
-
2017
- 2017-04-06 IL IL251627A patent/IL251627B/en unknown
- 2017-04-18 ZA ZA2017/02704A patent/ZA201702704B/en unknown
- 2017-05-02 CL CL2017001088A patent/CL2017001088A1/es unknown
-
2020
- 2020-09-10 JP JP2020151877A patent/JP2021001184A/ja not_active Withdrawn
-
2022
- 2022-12-23 US US18/088,272 patent/US12343381B2/en active Active
-
2025
- 2025-02-21 US US19/059,883 patent/US20250186552A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5382657A (en) * | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
| US5738846A (en) * | 1994-11-10 | 1998-04-14 | Enzon, Inc. | Interferon polymer conjugates and process for preparing the same |
| US20090035273A1 (en) * | 2006-08-18 | 2009-02-05 | Pepgen Corporation | Combination treatment method with interferon-tau |
| US20120310140A1 (en) * | 2010-12-01 | 2012-12-06 | Spinal Modulation, Inc. | Directed delivery of agents to neural anatomy |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12343381B2 (en) | Dosage regimen for pegylated interferon | |
| Gabrilove et al. | Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium | |
| Balkwill | Tumour necrosis factor | |
| CA2427194A1 (en) | Method for short-term and long-term drug dosimetry | |
| ES2860480T3 (es) | Anticuerpos neutralizantes de GM-CSF para su uso en el tratamiento de la artritis reumatoide o como analgésicos | |
| KR20030043924A (ko) | 에리트로포이에틴 투여에 의한 개선된 항-바이러스 및항-종양 화학 요법 | |
| US20230287075A1 (en) | Dual cytokine fusion proteins comprising multi-subunit cytokines | |
| JP2006528679A (ja) | コロナウイルス感染症及びサースを治療するための組成物及び方法 | |
| Guilhot et al. | Interferon therapy in chronic myelogenous leukemia | |
| WO2018017571A1 (en) | Uses of il-12 as a replacement immunotherapeutic | |
| ES2319777T3 (es) | Tratamiento de carcinoma de celulas renales. | |
| JP2022517211A (ja) | 二環式置換ピラゾロンアゾ誘導体の投与レジメン | |
| Jilma et al. | Demonstration of clinical comparability of the biosimilar filgrastim to Neupogen, in terms of safety and efficacy, in healthy volunteers and patients receiving myelosuppressive chemotherapy | |
| US20250195616A1 (en) | Method of using pegylated interferon-alpha | |
| ES2243166T3 (es) | Terapia de la leucemia mieloide cronica (cml). | |
| Mogharrabi et al. | Subcutaneous Administration of Anticancer Agents: A Narrative Review | |
| CN114028544A (zh) | 一种动员淋巴瘤和骨髓瘤干细胞的药物组合物 | |
| JP2004143113A (ja) | インターフェロン製剤及びその投与システム |